Relmada Therapeutics (RLMD) Operating Expenses (2012 - 2026)

Over the twelve months ended Jun 30, 2026, Relmada Therapeutics' Operating Expenses came in at $65.13 million, down 7.6% year-over-year; for FY2025, it was $59.1 million, down 29.6% from FY2024.

• Operating Expenses has declined for three consecutive years, with a five-year compound annual growth rate of -0.6% (FY2020 to FY2025).
• By year, Operating Expenses came in at $83.89 million in FY2024 (-19.1%), $103.7 million in FY2023 (-35.7%), $161.25 million in FY2022 (+28.3%) and $125.7 million in FY2021 (+106.6%).
• Five-year quarterly Operating Expenses spans a low of $10.22 million in Q2 2025 and a high of $45.51 million in Q2 2022.
• Year over year, Operating Expenses has now increased in each of the last three quarters, with an average decline of 11.1% over the last eight quarters.
• The high point for year-over-year Operating Expenses in five years was Q3 2021 (growth of 148.2%); the low point was Q3 2025 (a decline of 55.1%).
• Per Business Quant data, the three quarters before Q2 2026 came in at $19.46 million (Q1 2026), $20.33 million (Q4 2025) and $10.33 million (Q3 2025).